CD123 CAR-NK cell therapy(Beijing JD Biotech)

N/A

Report date: 2025/03/13 20:00:06

Base Information

Drug NameCD123 CAR-NK cell therapy(Beijing JD Biotech)
Drug Alias NameJD123JD-123
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsInterleukin-3 receptor subunit alpha modulators
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing JD Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking University People'S Hospital
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A